Ascelia Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Ascelia Pharma wird ein jährliches Gewinn- und Umsatzwachstum von 47.2% bzw. 76.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 71.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 31.5% betragen.

Wichtige Informationen

47.2%

Wachstumsrate der Gewinne

71.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	45.7%
Wachstumsrate der Einnahmen	76.2%
Zukünftige Eigenkapitalrendite	31.5%
Analystenabdeckung	Low
Zuletzt aktualisiert	09 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Mar 07

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Dec 09

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Nov 26

Gewinn- und Umsatzwachstumsprognosen

OM:ACE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (SEK Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	12	-60	-49	-49	2
12/31/2025	42	-13	-22	-19	2
12/31/2024	N/A	-65	-53	-52	2
9/30/2024	N/A	-62	-60	-60	N/A
6/30/2024	N/A	-62	-74	-74	N/A
3/31/2024	N/A	-89	-104	-104	N/A
12/31/2023	N/A	-109	-127	-127	N/A
9/30/2023	N/A	-152	-140	-140	N/A
6/30/2023	N/A	-157	-141	-141	N/A
3/31/2023	N/A	-139	-131	-131	N/A
12/31/2022	N/A	-131	-125	-125	N/A
9/30/2022	N/A	-113	-129	-129	N/A
6/30/2022	N/A	-115	-127	-127	N/A
3/31/2022	N/A	-126	-125	-125	N/A
12/31/2021	N/A	-126	-117	-117	N/A
9/30/2021	N/A	-127	-112	-112	N/A
6/30/2021	N/A	-113	-100	-100	N/A
3/31/2021	N/A	-111	-90	-90	N/A
12/31/2020	N/A	-99	-86	-86	N/A
9/30/2020	N/A	-90	-75	-75	N/A
6/30/2020	N/A	-88	-76	-76	N/A
3/31/2020	N/A	-71	-70	-70	N/A
12/31/2019	N/A	-66	-54	-54	N/A
9/30/2019	N/A	-46	-47	-47	N/A
6/30/2019	N/A	-37	-30	-30	N/A
3/31/2019	N/A	-30	-19	-19	N/A
12/31/2018	N/A	-23	-19	-19	N/A
9/30/2018	N/A	-22	-17	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (1.2%).

Ertrag vs. Markt: ACE wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ACE wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ACEDie Einnahmen des Unternehmens (76.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swedish (-0% pro Jahr).

Hohe Wachstumseinnahmen: ACEDie Einnahmen des Unternehmens (76.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ACEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (31.5%)

Ascelia Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 22% to kr9.75

Price target decreased by 61% to kr8.00

Price target decreased by 7.1% to kr19.50

Price target decreased to kr48.00

Price target decreased to kr59.00

Price target increased to kr64.00

Recent updates

Key Executive recently bought kr55k worth of stock

Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?

Ascelia Pharma AB (Publ) Announces Appointment of Marianne Kock as New Board Member

Ascelia Pharma AB (Publ) Presents Late-Breaking Abstract on Sparkle Data At the American Society of Nephrology Kidney Week Congress 2024

New major risk - Shareholder dilution

Ascelia Pharma AB (publ), Annual General Meeting, Apr 10, 2025

New major risk - Market cap size

Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?

VP of Pharmaceutical Development recently bought kr103k worth of stock

New major risk - Revenue and earnings growth

Price target increased by 22% to kr9.75

New major risk - Revenue and earnings growth

Ascelia Pharma AB (publ) Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study

Key Executive recently bought kr62k worth of stock

Price target decreased by 61% to kr8.00

New major risk - Revenue and earnings growth

Deputy CEO & Chief Commercial Officer recently bought kr170k worth of stock

Price target decreased by 7.1% to kr19.50

Ascelia Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 07, 2025

Ascelia Pharma AB (publ) Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE

New major risk - Share price stability

Chief Scientific Officer recently bought kr86k worth of stock

New major risk - Revenue and earnings growth

Insufficient new directors

Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?

Independent Director recently bought kr352k worth of stock

Ascelia Pharma AB (publ) Announces 71 Patients Have Completed the SPARKLE Study

Ascelia Pharma AB (Publ) Announces 65 Patients Completes the Sparkle Study

Price target decreased to kr48.00

Key Executive recently bought kr225k worth of stock

Ascelia Pharma AB (Publ) Announces New Data Show That the Pivotal Phase 3 Clinical Sparkle Study

Price target decreased to kr59.00

Ascelia Pharma AB Announces That the Nomination Committee in Preparation for the Annual General Meeting on 4 May 2023 Has Been Appointed

Ascelia Pharma Presents Results of Orviglance Food Effect Study At RSNA 2022 Showing Strong Liver Enhancement Both with Light Meal and in Fasting Condition

Ascelia Pharma AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Ascelia Pharma AB (Publ) Announces Resignation of Carl Bjartmar as CMO

Ascelia Pharma AB (publ) Announces Successful Final Results from Orviglance Hepatic Impairment Study

Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans

Ascelia Pharma AB (publ) Announces Change of CFO

Chief Commercial Officer recently bought kr310k worth of stock

Key Executive recently bought kr101k worth of stock

Chief Executive Officer recently bought kr459k worth of stock

Ascelia Pharma's Food Effect Study Shows Orviglance Image Enhancement of the Liver Is Not Reduced by Light Meal

Price target increased to kr64.00

Insufficient new directors

Ascelia Pharma Suspends Clinical Activities in Russia

Key Executive recently bought kr116k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Receives FDA Acceptance of IND Application for Oncoral Clinical Trial

Ascelia Pharma AB (publ) Announces Results from Orviglance comparison study to gadolinium presented at RSNA 2021

Chief Commercial Officer recently bought kr208k worth of stock

Chief Medical Officer recently bought kr260k worth of stock

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

Ascelia Pharma AB (publ) Announces Abstract for Orviglance Comparison Study to Gadolinium Accepted At the Radiology Conference RSNA

Ascelia Pharma AB (publ) Receives Conditional U.S. Food and Drug Administration Acceptance for Orviglance

Chief Executive Officer recently bought kr379k worth of stock

Companies Like Ascelia Pharma (STO:ACE) Are In A Position To Invest In Growth

Chief Executive Officer recently sold kr5.8m worth of stock

Chief Executive Officer exercised options to buy kr11m worth of stock.

Here's What Ascelia Pharma AB (publ)'s (STO:ACE) Shareholder Ownership Structure Looks Like

Chief Medical Officer recently bought kr392k worth of stock

Ascelia Pharma AB (publ) Presents Clinical Development Plan for Oncoral as a Novel Chemotherapy

Ascelia Pharma Gets US Patent for Second Generation Mangoral

Helena Wennerström Is The Independent Director of Ascelia Pharma AB (publ) (STO:ACE) And They Just Picked Up 125% More Shares

Independent Director recently bought kr469k worth of stock

Ascelia Pharma AB (Publ) Announces New Study Shows Mangoral's Lesion Visualization as Effective as Gadolinium Contrast Agent

New 90-day high: kr47.55

We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth

New 90-day high: kr43.35